0000318989-15-000053.txt : 20151002 0000318989-15-000053.hdr.sgml : 20151002 20151002171040 ACCESSION NUMBER: 0000318989-15-000053 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20151002 DATE AS OF CHANGE: 20151002 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: WuXi PharmaTech (Cayman) Inc. CENTRAL INDEX KEY: 0001403132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-83350 FILM NUMBER: 151141277 BUSINESS ADDRESS: STREET 1: 288 FUTE ZHONG ROAD STREET 2: WAIGAOQIAO FREE TRADE ZONE CITY: SHANGHAI STATE: F4 ZIP: 200131 BUSINESS PHONE: 86-21-5046-1111 MAIL ADDRESS: STREET 1: 288 FUTE ZHONG ROAD STREET 2: WAIGAOQIAO FREE TRADE ZONE CITY: SHANGHAI STATE: F4 ZIP: 200131 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FIL Ltd CENTRAL INDEX KEY: 0000318989 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: P.O. BOX H.M. 670 CITY: HAMILTON STATE: D0 ZIP: 00000 BUSINESS PHONE: 6175637100 MAIL ADDRESS: STREET 1: P.O. BOX H.M. 670 CITY: HAMILTON STATE: D0 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: FIL LTD DATE OF NAME CHANGE: 20080213 FORMER COMPANY: FORMER CONFORMED NAME: FIDELITY INTERNATIONAL LTD DATE OF NAME CHANGE: 19920929 SC 13G/A 1 20151002_5372610113GFIL96528.txt WUXI PHARMATECH SC 13G/A SCHEDULE 13G Amendment No. 2 WUXI PHARMATECH CAYMAN INC COMMON STOCK Cusip #G98079109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G98079109 Item 1: Reporting Person - FIL Limited Item 2: (a) [ ] (b) [ ] Item 4: Bermuda Item 5: 26,619,376 Item 6: 0 Item 7: 27,432,304 Item 8: 0 Item 9: 27,432,304 Item 11: 4.825% Item 12: FI Cusip #G98079109 Item 1: Reporting Person - Pandanus Partners, L.P. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 27,432,304 Item 8: 0 Item 9: 27,432,304 Item 11: 4.825% Item 12: PN Cusip #G98079109 Item 1: Reporting Person - Pandanus Associates, Inc. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 27,432,304 Item 8: 0 Item 9: 27,432,304 Item 11: 4.825% Item 12: CO Item 1(a). Name of Issuer: WUXI PHARMATECH CAYMAN INC Item 1(b). Address of Issuer's Principal Executive Offices: 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai, 200131 China Item 2(a). Name of Person Filing: FIL Limited Item 2(b). Address or Principal Business Office or, if None, Residence: Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda, HM19 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: G98079109 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 27,432,304 (b) Percent of Class: 4.825% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 26,619,376 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 27,432,304 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of WUXI PHARMATECH CAYMAN INC. No one other person's interest in the COMMON STOCK of WUXI PHARMATECH CAYMAN INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. In as much as the reporting persons are no longer the beneficial owners of more than five percent of the number of shares outstanding, the reporting persons have no further reporting obligation under Section 13(d) of the Securities and Exchange Commission thereunder, and the reporting persons have no obligation to amend this Statement if any material change occurs in the facts set forth herein. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. October 2, 2015 Date /s/ Scott C. Goebel Signature Scott C. Goebel Duly authorized under Power of Attorney effective as of May 5, 2014, by and on behalf of FIL Limited and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession number: 0000318989-14-000096. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIL INVESTMENT MANAGEMENT (HONG KONG) LIMITED FI FIL INVESTMENT MANAGEMENT (SINGAPORE) LIMITED FI FIL LIMITED FI Pandanus Partners, L.P. ("Pandanus") owns shares of FIL Limited ("FIL") voting stock. While the percentage of total voting power represented by these shares of FIL voting stock may fluctuate as a result of changes in the total number of shares of FIL voting stock outstanding from time to time, it normally represents more than 25% and less than 50% of the total votes which may be cast by all holders of FIL voting stock. Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus. Pandanus is owned by trusts for the benefit of members of the family of Edward C. Johnson 3d but disclaims that any such member is a beneficial owner of the securities reported on this Schedule 13G. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FIL, certain of its subsidiaries and affiliates, and other companies (collectively, the "FIL Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FIL Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on October 2, 2015, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of WUXI PHARMATECH CAYMAN INC at September 30, 2015. FIL Limited By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of May 5, 2014, by and on behalf of FIL Limited and its direct and indirect subsidiaries* Pandanus Partners, L.P. By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of May 2, 2014, by Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.* Pandanus Associates, Inc. By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of May 2, 2014, by and on behalf of Pandanus Associates, Inc.* * This power of attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession number: 0000318989-14-000096.